Canbridge Pharmaceuticals Inc. Releases Supplemental Announcement on Audited 2024 Financial Results
Canbridge Pharmaceuticals Inc. has issued a supplemental announcement regarding its audited financial results for the year ended December 31, 2024, as detailed in the 2024 Annual Report. The announcement clarifies that 534,375 Shares underlying RSUs vested during the reporting period, and the table on page 46 includes a correction, removing the irrelevant concept of "exercise" from the Post-IPO RSU Scheme. Additionally, the company provided further information on the write-off of its right of use assets related to its Boston, U.S. office and laboratory, which was vacated in the second half of 2024. Despite vacating the premises, the lease remained legally binding until February 28, 2025. As of December 31, 2024, the lease liabilities were recognized in the financial statements, in accordance with IFRS 16, as the lease obligations had not been legally extinguished by that date. The company assures that except for these disclosures, all other information in the 2024 Annual Report remains unchanged.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on September 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.